Overview

Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This study is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control when using NovoMix® 50 up to 12 months after initiation subjects with type 2 diabetes currently on a therapy with human biphasic insulin. An additional objective is also to observe the different regimes of starting and maintaining the treatment with NovoMix® 50 during one year.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Biphasic Insulins
Insulin
Insulin Aspart